Thomas Anish, Perzova Raisa, Abbott Lynn, Benz Patricia, Poiesz Michael J, Dube Syamalima, Loughran Thomas, Ferrer Jorge, Sheremata William, Glaser Jordan, Leon-Ponte Matilde, Poiesz Bernard J
Department of Medicine, State University of New York, Upstate Medical University, Syracuse, 13202, USA.
AIDS Res Hum Retroviruses. 2010 Jan;26(1):33-40. doi: 10.1089/aid.2009.0124.
Samples were obtained from 53 large granular lymphocytic leukemia (LGLL) patients and 10,000 volunteer blood donors (VBD). Sera were screened in an HTLV-1 enzyme immunoassay (EIA) and further analyzed in peptide-specific Western blots (WB). DNAs were analyzed by HTLV-1, -2, -3, and -4-specific PCR. Forty four percent of LGLL patients vs. 0.12 % of VBD had anti-HTLV antibodies via EIA (p < 0.001). WB and PCR revealed that four LGLL patients (7.5%) vs. one VBD patient (0.01%) were infected with HTLV-2 (p < 0.001), suggesting an HTLV-2 etiology in a minority of cases. No LGLL patient was positive for HTLV-1, -3, or -4, whereas only one EIA-positive VBD was positive for HTLV-1 and none for HTLV-3 or -4. The HTLV EIA-positive, PCR-negative LGLL patients' sera reacted to epitopes within HTLV p24 gag and gp21 env. Other then the PTLV/BLV viruses, human endogenous retroviral element HERV K10 was the only sequence homologous to these two HTLV peptides, raising the possibility of cross-reactivity. Although three LGLL patients (5.7%) vs. none of 110 VBD patients tested positive for antibodies to the homologous HERV K10 peptide (p = 0.03), the significance of the anti-HTLV seroreactivity observed in many LGLL patients remains unclear. Interestingly, out of 36 HTLV-1-positive control subjects, 3 (8%) (p = 0.014) were positive for antibodies to HERV K10; all three had myelopathy. Out of 64 HTLV-2-positive control subjects 16 (25%) (p = <0.001) were positive for HERV K10 antibodies, and 4 (6%) of these had myelopathy. Out of 22 subjects with either HTLV-1 or -2 myelopathy, 7 (31.8%) were positive for HERV K10 antibodies, and out of 72 HTLV-infected subjects without myelopathy, 12 (16.7%) were positive for anti-HERV K10 antibodies (p = 0.11). The prevalence of anti-HERV K10 antibodies in these populations and the clinical implications thereof need to be pursued further.
从53例大颗粒淋巴细胞白血病（LGLL）患者和10000名志愿献血者（VBD）中获取样本。血清在HTLV - 1酶免疫测定（EIA）中进行筛查，并在肽特异性免疫印迹法（WB）中进一步分析。DNA通过HTLV - 1、- 2、- 3和- 4特异性聚合酶链反应（PCR）进行分析。通过EIA检测，44%的LGLL患者与0.12%的VBD具有抗HTLV抗体（p < 0.001）。WB和PCR显示，4例LGLL患者（7.5%）与1例VBD患者（0.01%）感染了HTLV - 2（p < 0.001），提示少数病例存在HTLV - 2病因。没有LGLL患者HTLV - 1、- 3或- 4呈阳性，而只有1例EIA阳性的VBD患者HTLV - 1呈阳性，HTLV - 3或- 4均为阴性。HTLV EIA阳性、PCR阴性的LGLL患者血清与HTLV p24 gag和gp21 env内的表位发生反应。除了PTLV/BLV病毒外，人类内源性逆转录病毒元件HERV K10是与这两种HTLV肽唯一同源的序列，增加了交叉反应的可能性。尽管3例LGLL患者（5.7%）与110例检测的VBD患者中无一例对同源HERV K10肽抗体呈阳性（p = 0.03），但在许多LGLL患者中观察到的抗HTLV血清反应性的意义仍不清楚。有趣的是，在36例HTLV - 1阳性对照受试者中，3例（8%）（p = 0.014）对HERV K10抗体呈阳性；这3例均患有脊髓病。在64例HTLV - 2阳性对照受试者中，16例（25%）（p = <0.001）对HERV K10抗体呈阳性，其中4例（6%）患有脊髓病。在22例患有HTLV - 1或- 2脊髓病的受试者中，7例（31.8%）对HERV K10抗体呈阳性，在72例无脊髓病的HTLV感染受试者中，12例（16.7%）抗HERV K10抗体呈阳性（p = 0.11）。这些人群中抗HERV K10抗体的患病率及其临床意义需要进一步研究。
